Monday, 11 Aug 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    HR Path Strengthens Global Presence with Strategic Acquisition of PredictiveHR
    11/08/2025
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    Manulife to Acquire Comvest Credit Partners, Creating a Leading Private Credit Platform
    10/08/2025
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    Bybit Crypto Insights Report: Everything You Need to Know About Project Crypto
    10/08/2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    MiTAC Computing Partners with Industry Leaders on Open AI Server Solutions at OCP APAC Summit 2025
    09/08/2025
    NOTICE OF SETTLEMENT APPROVAL
    NOTICE OF SETTLEMENT APPROVAL
    09/08/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • june
  • july
  • global
  • Business
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

PRNW Agency
Last updated: 16/06/2025 8:52 AM
PRNW Agency
Share
5 Min Read
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHARE
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA

SHANGHAI, June 16, 2025 /PRNewswire/ — Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged six years and above.

- Advertisement -

First Methylphenidate Combination Drug Poised to Benefit Patients in China

- Advertisement -

Azstarys (AK0901) is the first and currently the sole globally approved ADHD combination therapeutic pairing immediate-release dexmethylphenidate (d-MPH) with the prodrug serdexmethylphenidate (SDX). Approved by the U.S. FDA in 2021, Azstarys represents a new generation of methylphenidate medications, providing a dual-phase release profile that offers both rapid onset and sustained symptom control. This novel formulation sets a new benchmark in the management of ADHD for safety, efficacy, and convenience of administering for patients, making it a potential best-in-class ADHD therapeutic drug.

Pharmacokinetic Property: Biphasic Release for Rapid Onset and Whole-Day Symptom Control

- Advertisement -
  • Rapid onset: Immediate-release d-MPH ensures symptom relief within 30 minutes, offering fast control over core ADHD symptoms.
  • Extended control: SDX is metabolized slowly into d-MPH in intestine over time, ensuring up to 13 hours of therapeutic effect with reduced risk of evening rebound symptoms.
  • Stable Release Profile: Designed to support the full span of a patient’s day—from school or work to evening activities—Azstarys enhances adherence and minimizes sleep disruptions, suiting both pediatric and adult populations.

Abuse-Deterrent Design

- Advertisement -

Azstarys incorporates an inherent abuse-deterrent design through the inclusion of SDX, which undergoes slow conversion in the gastrointestinal tract. This limits peak plasma concentrations of d-MPH and significantly reduces the potential for misuse via non-oral routes—a key public health consideration in ADHD pharmacotherapy.

Robust Clinical Efficacy and Safety Confirmed in China Phase III Trial

- Advertisement -
  • In a multicenter Phase III trial spanning eight leading clinical hospitals in China, Azstarys demonstrated statistically significant improvements over placebo in primary and secondary efficacy endpoints.
  • The study reported no drug related serious adverse events, affirming Azstarys’s favorable safety and tolerability profile, critical for long-term use in pediatric settings.

Transforming ADHD Treatment Paradigm in China

- Advertisement -

As the third-generation methylphenidate therapy, Azstarys delivers a new standard of care in ADHD management by integrating rapid onset and full-day symptom control into a single dose. Its future approval in China would mark the introduction of the first ADHD combination medication to the market, offering a better option for patients, families, and physicians.

Dr. Jim Wu, CEO of ArkBio, stated, 

- Advertisement -

“The acceptance of Azstarys’ NDA and its designation for Priority Review by the NMPA reflect regulatory authority’s favorable opinions in our science and clinical study results. ADHD remains critically underserved in China, and Azstarys is designed to directly meet the needs of patients who require both immediate symptom relief and sustained control. We are grateful to our investigators, trial participants, collaborators, and the NMPA for this milestone and we look forward to accelerating access to this important therapeutic in China market.”

- Advertisement -

Azstarys® is a registered trademark of Corium, LLC in the United States.

About ArkBio

ArkBio is a global biotech company focused on developing innovative therapeutics for respiratory, infectious, and pediatric diseases. Founded in 2014, it has built core technology platforms and a differentiated R&D pipeline through in-house R&D efforts and external collaboration. Key drug assets include ziresovir (AK0529), the first direct-acting RSV antiviral with positive pivotal phase III results, and Azstarys (AK0901), an FDA-approvedADHD therapeutic drug. 

- Advertisement -

ArkBio has established strategic partnerships with several multinational pharmaceutical companies and academic institutes, including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.

- Advertisement -

For more information about the company, please visit our website:www.arkbiosciences.com

Logo – https://mma.prnewswire.com/media/2516404/5367504/ArkBio_Logo.jpg

- Advertisement -

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa-302481852.html

- Advertisement -
HIMSS and Informa Markets Partner to Accelerate Digital Health Transformation with Co-Located Conferences in Malaysia for International Healthcare Week
Nexteer Breaks Ground on New Manufacturing Facility in Liuzhou, China
Micropolis Holding Company Filed Annual Report on Form 20-F for the Year Ended December 31, 2024
Run Legacy Launches Planet’s First Dedicated Sustainable Sports Brand Retail Platform
Tribesigns and Sihoo Unveil Co-Branded Furniture Promotions to Elevate Home Office Working Experience on Prime Day
TAGGED:acceptedadministrationannouncedapplicationarkarkbioazstarysbiopharmaceuticalcapsulesdesignationdrugextendedreleasegrantedindicatedinvestigationaljuneltdmedicalnationalndanmpaofficiallypatientspriorityproductsreviewserdexmethylphenidatedexmethylphenidateshanghaitherapeutictoday
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

NOTICE OF SETTLEMENT APPROVAL
Travel

Hikal introduces Digital Infrastructure at 130 year old Zilla Parishad School in Alibaug

05/07/2025
NOTICE OF SETTLEMENT APPROVAL
Business

BugleRock Capital’s Global AUA Surpasses $4 Billion USD

08/07/2025
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Health

Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease

03/06/2025

GENESIS MAGMA RACING TAKES POSITIVES FROM FIRST 24 HOURS OF LE MANS PARTICIPATION

17/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?